High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
A Prospective, Randomized, Phase ll Clinical Trial of Single-agent Treatment With Different Doses of Sulfamethoxazole Furmonertinib in Patients With Advanced, Metastatic Lung Adenocarcinoma Who Have Progressed After First- or Second-line Treatment With EGFR-TKl Osimertinib
Sponsor: Changhai Hospital
This PHASE2 trial investigates Non-Small Cell Lung Cancer and is currently actively recruiting participants. Changhai Hospital leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Mar 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
First recorded
May 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changhai Hospital
- Fujian Provincial Hospital
- Second Affiliated Hospital of Wannan Medical College
- Shanghai Changzheng Hospital
- Shanghai Chest Hospital
- The First Affiliated Hospital of Bengbu Medical University
- The First People's Hospital of Changzhou
- The General Hospital of Eastern Theater Command
For direct contact, visit the study record on ClinicalTrials.gov .